Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-To-Severe Rheumatoid Arthritis

Hicks, K., Earnshaw, S., Shaw, JW., & Cifaldi, M. (2012). Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-To-Severe Rheumatoid Arthritis. Value in Health, 15(7), A439-A440.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Meet the Experts

View All Experts
Stephanie Earnshaw
Navigate to Stephanie Earnshaw

Stephanie Earnshaw